No reported deaths due to Dengvaxia vaccine — Sanofi

Sanofi confirms suspected safety issue with dengue vaccine
Anti-dengue vaccine in Philippines 'may worsen symptoms'

04 Diciembre, 2017

The secretary said there haven't been any reports of severe dengue infection among those vaccinated, and he noted that the government would profile all those who received the vaccination and heighten its surveillance mechanisms.

"As far as we are made aware, there are no reported deaths that are related to dengue vaccination", said Dr. Ruby Dizon, a medical director at the French firm. CVS on Sunday said it planned to buy Aetna for $69 billion.

The Philippines is prepared for a "worst-case scenario" following warnings that an anti-dengue vaccine administered to thousands of children may worsen the disease in some cases, a health official said Saturday.

Sales last year came in at €55m, well short of the €200m predicted by analysts - and has headed south in 2017, making just €22m in the first nine months of this year and €4m in the third quarter - a near 90% drop.

Presidential spokesperson Harry Roque said those behind the botched dengue immunization program will be held responsible and that the Department of Health is now closely monitoring those who have received the Dengvaxia vaccine.

The manufacturer of a dengue vaccine whose use was suspended by the Philippines last week after a study showed risks of severe cases in people without previous infection says it is working to resolve those fears.

Pharmaceutical giant Sanofi Pasteur on Monday said no deaths were caused by its anti-dengue vaccine Dengvaxia.

Dengue is the most widespread mosquito-borne disease in the world, with nearly 400 million people infected every year.

In 2016, the Philippines became the first country to implement the use of Dengvaxia through a school-based dengue immunization program, which initially covered Grade 4 students in the National Capital Region, Central Luzon, and CALABARZON (Cavite, Laguna, Rizal, Quezon).

Sanofi executives also stressed that the drug would still be beneficial to majority of Filipinos, given that nine out of ten of them aged nine to 14 years old had already been infected with dengue but not all of them were hospitalized for the illness, given that three-fourths of dengue cases were asymptomatic.

Sanofi on Monday said there have been no reported deaths in the Philippines related to its vaccine.

"We need a database to identify the 70,000 affected children and know where they are exactly located in order for the government to keep track of their health and prepare the needed resources and logistics that will allow for quick and appropriate medical responses, if needed".

Peing said she would not recommend Dengvaxia for those who have never been infected.

Mas noticias